Company profilePharmaceutical#1071 of 1,318 in Pakistan✓ No DRAP alerts

Venture Pharmaceuticals (Pvt.) Ltd DSL: 291

Pharmaceutical company · 2 brands · 5 molecules

2 registered products 5 pharmaceutical brands 5 distinct molecules 0 DRAP alerts

Company overview

2
registered products
5
pharmaceutical brands
5
distinct molecules
0
therapeutic classes
0
DRAP alerts

Venture Pharmaceuticals (Pvt.) Ltd DSL: 291 is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 2 product registrations across 5 distinct molecules. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Venture

3 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

3
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
20253

Top molecules by brand count

Ceftriaxone Sodium ...... 250 Mg1 brand
Ceftriaxone Sodium ...... 500 Mg1 brand
Ceftriaxone Sodium ...... 1000 Mg1 brand
Doxycycline Hyclate ...... 100 Mg1 brand

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official4 products · Rs 209.09 – Rs 712.8
Median across source: Rs 428.03

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

MEDIATE PHARMACEUTICALS (PVT) LTD holds 113 molecules not in this portfolio
AcyclovirAlendronateAmlodipineAmoxicillinAmpicillinAmpicillin Base
SHAIGAN PHARMACEUTICALS (PVT) LTD. holds 138 molecules not in this portfolio
AlbendazoleAmikacinAmlodipineAmlodipine BasylateArtemetherAscorbic Acid
HIGH - Q INTERNATIONAL holds 139 molecules not in this portfolio
000 I.UAcetyl L-CarnitineAmikacinAmlodipineAnastrozoleAprepitant

Get the full profile for Venture

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.